surpass cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Certain individuals are more likely to develop B12 deficiency, including those with: Pernicious anemia Gastrointestinal conditions (such as Crohns disease or celiac disease) A history of gastrointestinal surgery Difficulty absorbing nutrients due to age or other medical conditions For these patients, vitamin B12 injections are an effective option because they deliver the nutrient directly into the bloodstream, bypassing the digestive system and ensuring optimal absorption

However, this typically requires ongoing treatment to maintain

The effects you can expect with systematic use include: Smoothing of fine mimic lines

He calls BPC-157 "still the Wild West" because it lacks human RCTs, yet he prescribes GLP-1 agonists clinically and flagged the 39% lean mass loss problem from the STEP 1 trial before most physicians paid attention